NewcelX Ltd. (NCEL): Cash & Equivalents
$2.20M
As of 2025-12-31
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.20M | +238.6% | 2026-04-29, Balance as of period end |
| 2024-12-31 | $650.0K | -43.3% | 2026-04-29, Balance as of period end |
| 2023-12-31 | $1.15M | n/c | 2026-04-29, Balance as of period end |
| 2022-12-31 | $8.95M | +64.8% | 2024-05-15, Balance as of period end |
| 2021-12-31 | $5.43M | n/m | 2023-05-05, Balance as of period end |
| 2020-12-31 | $93.7K | -57.5% | 2022-03-24, Balance as of period end |
| 2019-12-31 | $220.3K | n/a | 2021-05-14, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| NewcelX Ltd. (NCEL) | 2025-12-31 | $2.20M | +238.6% |
| Curanex Pharmaceuticals Inc (CURX) | 2025-12-31 | $5.00M | n/a |
| Revelation Biosciences, Inc. (REVB) | 2025-12-31 | $10.70M | +64.6% |
| MetaVia Inc. (MTVA) | 2025-12-31 | $10.28M | -35.8% |
| Mira Pharmaceuticals, Inc. (MIRA) | 2025-12-31 | $6.35M | +124.0% |
| Decoy Therapeutics Inc. (DCOY) | 2025-12-31 | $10.71M | +339.9% |
| Lantern Pharma Inc. (LTRN) | 2025-12-31 | $4.42M | -41.1% |
| PRF Technologies Ltd. (PRFX) | 2025-12-31 | $3.12M | -26.7% |
| Anebulo Pharmaceuticals, Inc. (ANEB) | 2025-06-30 | $11.63M | +275.8% |
Compare NCEL, CURX, REVB, MTVA side by side · Screen every company in Pharmaceutical Preparations ↗